Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague–Dawley rats: Dose–response, and biochemical and pharamacokinetic parameters

• Published in: Toxicology (Amsterdam) 2005-11, Vol.215 (1), p.149-169
• Main Authors: Luebker, Deanna J., York, Raymond G., Hansen, Kristen J., Moore, John A., Butenhoff, John L.
• Format: Article
• Language: English
• Subjects: Alkanesulfonic Acids - pharmacokinetics; Alkanesulfonic Acids - toxicity; Animals; Animals, Newborn; Biological and medical sciences; Birth Weight - drug effects; Blood Glucose - analysis; Dose-Response Relationship, Drug; Dose–response; Female; Fluorocarbons - pharmacokinetics; Fluorocarbons - toxicity; Lipids - analysis; Liver - drug effects; Male; Mechanism; Medical sciences; Mevalonic Acid - analysis; Milk - chemistry; Perfluorooctanesulfonate; Perinatal mortality; PFOS; Pharmacokinetics; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Thyroid Hormones - analysis; Toxicity Tests; Toxicology
• ISSN: 0300-483X; 1879-3185
• DOI: 10.1016/j.tox.2005.07.019

Perfluorooctanesulfonate (PFOS) is a widely distributed, environmentally persistent acid found at low levels in human, wildlife, and environmental media samples. Neonatal mortality has been observed following PFOS exposure in a two-generation reproduction study in rats and after dosing pregnant rats and mice during gestation. Objectives of the current study were to better define the dose–response curve for neonatal mortality in rat pups born to PFOS-exposed dams and to investigate biochemical and pharmacokinetic parameters potentially related to the etiology of effects observed in neonatal rat pups. In the current study, additional doses of 0.8, 1.0, 1.2, and 2.0 mg/kg/day were included with original doses used in the two-generation study of 0.4 and 1.6 mg/kg/day in order to obtain data in the critical range of the dose–response curve. Biochemical parameters investigated in dams and litters included: (1) serum lipids, glucose, mevalonic acid, and thyroid hormones; (2) milk cholesterol; and (3) liver lipids. Pharmacokinetic parameters investigated included the interrelationship of administered oral dose of PFOS to maternal body burden of PFOS and the transfer of maternal body burden to the fetus in utero and pup during lactation, as these factors may affect neonatal toxicity. Dosing of dams occurred for 6 weeks prior to mating with untreated breeder males, through confirmed mating, gestation, and day four of lactation. Dose levels for the dose–response and etiological investigation were 0.0, 0.4, 0.8, 1.0, 1.2, 1.6, and 2.0 mg/kg/day PFOS. Statistically significant decreases in gestation length were observed in the 0.8 mg/kg and higher dose groups. Decreases in viability through lactation day 5 were observed in the 0.8 mg/kg and higher dose groups, becoming statistically significant in the 1.6 and 2.0 mg/kg dose groups. Reduced neonatal survival did not appear to be the result of reductions in lipids, glucose utilization, or thyroid hormones. The endpoints of gestation length and decreased viability were positively correlated, suggesting that late-stage fetal development may be affected in pups exposed to PFOS in utero and may contribute to the observed mortality. Benchmark dose (BMD) estimates for decreased gestation length, birth weight, pup weight on lactation day 5, pup weight gain through lactation day 5, and viability resulted in values ranging from 0.27 to 0.89 mg/kg/day for the lower 95% confidence limit of the BMD 5 (BMDL 5). Results of analyses fo